We next examined how the timing of MYC inactivation contributed to recurrence or complete regression by administering doxycycline either: (a) when the tumor was already large (0.8 cm3); or (b) when the tumor was small (immediately after T-ALL cell injection). This evidence concerns the gene MYC and acute lymphoblastic leukemia.